Abstract Number: 1472 • ACR Convergence 2024
Achievement of Low Disease Activity/Remission in Guselkumab-Treated Patients with Moderately-Highly Active Psoriatic Arthritis Regardless of Baseline Characteristics: Pooled Post-Hoc Analysis of Two Phase 3/Randomized Studies
Background/Purpose: Guselkumab (GUS), a fully human IL-23p19-subunit inhibitor, has demonstrated multidomain efficacy (swollen/tender joints, psoriasis, enthesitis and dactylitis) in patients (pts) with active PsA in…Abstract Number: 1935 • ACR Convergence 2024
Timely Referral of Patients with Inflammatory Rheumatic Diseases to Rheumatology: Validation of a Referral Algorithm with Frontline Physicians
Background/Purpose: Early referral of patients with chronic inflammatory rheumatic diseases (CIRDs) to rheumatology is essential to reduce diagnostic delays and improve long-term prognosis. Referral strategies…Abstract Number: 2319 • ACR Convergence 2024
Investigating the Association of Serum Metabolites with Psoriatic Arthritis Musculoskeletal Disease Patterns
Background/Purpose: Accurate assessment of disease patterns may be important for appropriate management of psoriatic arthritis (PsA). Ultrasonography (USG) is a highly accurate, sensitive, and non-invasive…Abstract Number: 2336 • ACR Convergence 2024
Patients with Psoriasis with a Positive Psoriasis Epidemiology Screening Tool (PEST): Similarities and Differences Compared to PsA and Patients with Psoriasis and a Negative PEST
Background/Purpose: Identifying patients at risk for developing psoriatic arthritis (PsA) may allow for accelerated diagnosis and treatment and improve long term outcomes for these patients.…Abstract Number: 2357 • ACR Convergence 2024
Longitudinal Evaluation of Neutrophil-to-Lymphocyte Ratio in Guselkumab-Treated Patients with Psoriatic Disease and Levels of Systemic Inflammation Associated with Elevated Cardiovascular Risk: Post-hoc Analysis of 4 Phase 3, Randomized, Controlled Studies
Background/Purpose: Psoriatic disease (PsD) is associated with an increased risk of cardiovascular (CV) disease. Neutrophil-to-lymphocyte ratio (NLR) is a biomarker of systemic inflammation; NLR ≥2.5…Abstract Number: 2638 • ACR Convergence 2024
Defining Sonographic Enthesitis in Psoriatic Arthritis: Developing a Data- and Expert-driven Diagnostic Criteria for Inflammatory Enthesitis at the Single Enthesis Level
Background/Purpose: Clinical enthesitis occurs in 30-40% of psoriatic arthritis (PsA) patients, but its clinical diagnosis is challenging due to similarities to non-specific entheseal pain. Despite…Abstract Number: 0074 • ACR Convergence 2024
Tofacitinib Therapy Ameliorates Inflammation in a Mouse Model of Psoriasis and Arthritis by Inducing Type 2 Immunity
Background/Purpose: Psoriatic arthritis (PsA), a chronic progressive inflammatory arthritis, affects peripheral joints and causes patient disability. PsA patients also have skin plaques initiated by activation…Abstract Number: 0384 • ACR Convergence 2024
Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study
Background/Purpose: Ustekinumab (UST), an interleukin‑12/23p40 antagonist, is currently approved for juvenile psoriatic arthritis (jPsA) solely in the United States (US). Although a phase 3 study…Abstract Number: 0594 • ACR Convergence 2024
Real-world Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-17 Inhibitors: A 16-week Multicenter Retrospective Review
Background/Purpose: While biologic switching is common in routine clinical practice, limited information exists on switching within class from another IL-17i to bimekizumab. We conducted a…Abstract Number: 1045 • ACR Convergence 2024
Impact of Stable Rheumatologic Therapy on Outcomes of Depression in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Background/Purpose: Rheumatic diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PA), and systemic lupus erythematosus (SLE) can significantly impact quality of life. This burden extends…Abstract Number: 1444 • ACR Convergence 2024
Characterization and Comparison of MRI Findings in Axial Spondyloarthritis, Axial Psoriatic and Chronic Non-inflammatory Back Pain
Background/Purpose: MRI of the sacroiliac joints (SIJ) is part of the evaluation of patients with suspected axial spondyloarthritis (axSpA). However, sacroiliitis (SI) could be a…Abstract Number: 1473 • ACR Convergence 2024
Patient-Reported Symptoms Improved with Stringent Control of Swollen Joints in Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
Background/Purpose: PsA is characterized by joint and skin inflammation, and associated with debilitating symptoms of pain and fatigue.1 Previous research has shown that pain and…Abstract Number: 1970 • ACR Convergence 2024
Validation of Handheld Ultrasound Devices for Point of Care Use in Rheumatology: Interim Analysis for Enthesitis
Background/Purpose: Ultrasonography (US) has experienced a rapid evolution in rheumatology. Despite many advantages being repeatedly shown, several barriers persist, equipment cost being an important one.…Abstract Number: 2320 • ACR Convergence 2024
Nailfold Videocapillaroscopy Findings in Patients with Psoriatic Disease: Is There a Distinctive Psoriatic Pattern?
Background/Purpose: The utility of nailfold videocapillaroscopy (NVC) in conditions such as systemic sclerosis and primary Raynaud´s phenomenon is well known. Whether patients with psoriatic disease…Abstract Number: 2337 • ACR Convergence 2024
Patient Characteristics and Outcomes of Emergency Visits in Psoriatic Arthritis: Results from the U.S. Nationwide Emergency Department Sample (NEDS)
Background/Purpose: Compared with the general population, patients with psoriatic arthritis (PsA) have a higher risk of comorbidities and all-cause mortality. They are also at increased…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 81
- Next Page »